不同种族和族裔老年人的神经影像和生物流体生物标志物的认知范围。

IF 12.5 1区医学 Q1 CELL BIOLOGY

Ageing Research Reviews Pub Date : 2024-09-19 DOI:10.1016/j.arr.2024.102507

Wei-en Wang , Breton M. Asken , Jesse C. DeSimone , Shellie-Anne Levy , Warren Barker , Jacob A. Fiala , Idaly Velez-Uribe , Rosie E. Curiel Cid , Monica Rósselli , Michael Marsiske , Malek Adjouadi , David A. Loewenstein , Ranjan Duara , Glenn E. Smith , Melissa J. Armstrong , Lisa L. Barnes , David E. Vaillancourt , Stephen A. Coombes

{"title":"不同种族和族裔老年人的神经影像和生物流体生物标志物的认知范围。","authors":"Wei-en Wang , Breton M. Asken , Jesse C. DeSimone , Shellie-Anne Levy , Warren Barker , Jacob A. Fiala , Idaly Velez-Uribe , Rosie E. Curiel Cid , Monica Rósselli , Michael Marsiske , Malek Adjouadi , David A. Loewenstein , Ranjan Duara , Glenn E. Smith , Melissa J. Armstrong , Lisa L. Barnes , David E. Vaillancourt , Stephen A. Coombes","doi":"10.1016/j.arr.2024.102507","DOIUrl":null,"url":null,"abstract":"<div><div>Neuroimaging and biofluid biomarkers provide a proxy of pathological changes for Alzheimer’s disease (AD) and are useful in improving diagnosis and assessing disease progression. However, it is not clear how race/ethnicity and different prevalence of AD risks impact biomarker levels. In this narrative review, we survey studies focusing on comparing biomarker differences between non-Hispanic White American(s) (NHW), African American(s) (AA), Hispanic/Latino American(s) (HLA), and Asian American(s) with normal cognition, mild cognitive impairment, and dementia. We found no strong evidence of racial and ethnic differences in imaging biomarkers after controlling for cognitive status and cardiovascular risks. For biofluid biomarkers, in AA, higher levels of plasma Aβ42/Aβ40, and lower levels of CSF total tau and p-tau 181, were observed after controlling for <em>APOE</em> status and comorbidities compared to NHW. Examining the impact of AD risks and comorbidities on biomarkers and their contributions to racial/ethnic differences in cognitive impairment are critical to interpreting biomarkers, understanding their generalizability, and eliminating racial/ethnic health disparities.</div></div>","PeriodicalId":55545,"journal":{"name":"Ageing Research Reviews","volume":"101 ","pages":"Article 102507"},"PeriodicalIF":12.5000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Neuroimaging and biofluid biomarkers across race and ethnicity in older adults across the spectrum of cognition\",\"authors\":\"Wei-en Wang , Breton M. Asken , Jesse C. DeSimone , Shellie-Anne Levy , Warren Barker , Jacob A. Fiala , Idaly Velez-Uribe , Rosie E. Curiel Cid , Monica Rósselli , Michael Marsiske , Malek Adjouadi , David A. Loewenstein , Ranjan Duara , Glenn E. Smith , Melissa J. Armstrong , Lisa L. Barnes , David E. Vaillancourt , Stephen A. Coombes\",\"doi\":\"10.1016/j.arr.2024.102507\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Neuroimaging and biofluid biomarkers provide a proxy of pathological changes for Alzheimer’s disease (AD) and are useful in improving diagnosis and assessing disease progression. However, it is not clear how race/ethnicity and different prevalence of AD risks impact biomarker levels. In this narrative review, we survey studies focusing on comparing biomarker differences between non-Hispanic White American(s) (NHW), African American(s) (AA), Hispanic/Latino American(s) (HLA), and Asian American(s) with normal cognition, mild cognitive impairment, and dementia. We found no strong evidence of racial and ethnic differences in imaging biomarkers after controlling for cognitive status and cardiovascular risks. For biofluid biomarkers, in AA, higher levels of plasma Aβ42/Aβ40, and lower levels of CSF total tau and p-tau 181, were observed after controlling for <em>APOE</em> status and comorbidities compared to NHW. Examining the impact of AD risks and comorbidities on biomarkers and their contributions to racial/ethnic differences in cognitive impairment are critical to interpreting biomarkers, understanding their generalizability, and eliminating racial/ethnic health disparities.</div></div>\",\"PeriodicalId\":55545,\"journal\":{\"name\":\"Ageing Research Reviews\",\"volume\":\"101 \",\"pages\":\"Article 102507\"},\"PeriodicalIF\":12.5000,\"publicationDate\":\"2024-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ageing Research Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1568163724003258\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CELL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ageing Research Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1568163724003258","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

神经影像和生物流体生物标志物可代表阿尔茨海默病（AD）的病理变化，有助于改善诊断和评估疾病进展。然而，目前还不清楚种族/民族和不同的阿兹海默症发病率对生物标志物水平有何影响。在这篇叙述性综述中，我们调查了一些研究，重点是比较非西班牙裔美国白人（NHW）、非洲裔美国人（AA）、西班牙裔/拉丁美洲裔美国人（HLA）和亚裔美国人在认知正常、轻度认知障碍和痴呆症情况下的生物标志物差异。在控制认知状况和心血管风险后，我们没有发现成像生物标志物存在种族和民族差异的有力证据。在生物流体生物标志物方面，在控制了APOE状态和合并症后，观察到AA的血浆Aβ42/Aβ40水平高于NHW，CSF总tau和p-tau 181水平低于NHW。研究注意力缺失症风险和合并症对生物标志物的影响及其对认知障碍的种族/民族差异的贡献，对于解释生物标志物、了解其普遍性以及消除种族/民族健康差异至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Neuroimaging and biofluid biomarkers across race and ethnicity in older adults across the spectrum of cognition

Neuroimaging and biofluid biomarkers provide a proxy of pathological changes for Alzheimer’s disease (AD) and are useful in improving diagnosis and assessing disease progression. However, it is not clear how race/ethnicity and different prevalence of AD risks impact biomarker levels. In this narrative review, we survey studies focusing on comparing biomarker differences between non-Hispanic White American(s) (NHW), African American(s) (AA), Hispanic/Latino American(s) (HLA), and Asian American(s) with normal cognition, mild cognitive impairment, and dementia. We found no strong evidence of racial and ethnic differences in imaging biomarkers after controlling for cognitive status and cardiovascular risks. For biofluid biomarkers, in AA, higher levels of plasma Aβ42/Aβ40, and lower levels of CSF total tau and p-tau 181, were observed after controlling for APOE status and comorbidities compared to NHW. Examining the impact of AD risks and comorbidities on biomarkers and their contributions to racial/ethnic differences in cognitive impairment are critical to interpreting biomarkers, understanding their generalizability, and eliminating racial/ethnic health disparities.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ageing Research Reviews 医学-老年医学

CiteScore

19.80

自引率

2.30%

发文量

216

审稿时长

55 days

期刊介绍： With the rise in average human life expectancy, the impact of ageing and age-related diseases on our society has become increasingly significant. Ageing research is now a focal point for numerous laboratories, encompassing leaders in genetics, molecular and cellular biology, biochemistry, and behavior. Ageing Research Reviews (ARR) serves as a cornerstone in this field, addressing emerging trends. ARR aims to fill a substantial gap by providing critical reviews and viewpoints on evolving discoveries concerning the mechanisms of ageing and age-related diseases. The rapid progress in understanding the mechanisms controlling cellular proliferation, differentiation, and survival is unveiling new insights into the regulation of ageing. From telomerase to stem cells, and from energy to oxyradical metabolism, we are witnessing an exciting era in the multidisciplinary field of ageing research. The journal explores the cellular and molecular foundations of interventions that extend lifespan, such as caloric restriction. It identifies the underpinnings of manipulations that extend lifespan, shedding light on novel approaches for preventing age-related diseases. ARR publishes articles on focused topics selected from the expansive field of ageing research, with a particular emphasis on the cellular and molecular mechanisms of the aging process. This includes age-related diseases like cancer, cardiovascular disease, diabetes, and neurodegenerative disorders. The journal also covers applications of basic ageing research to lifespan extension and disease prevention, offering a comprehensive platform for advancing our understanding of this critical field.